Clinical trials: Advanced Pancreatic Cancer
Pancreatic Neoplasms
Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
The goal is to assess survival and patterns of failure in patients treated with Gemzar-based chemoradiation and TNP-470 for locally advanced adenocarcinoma of the pancreas.
- Trial name
- NCT00038701
- Testing
- TNP-470
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Pancreatic Cancer
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX…
- Trial name
- DIRECT (NCT03899636)
- Testing
- Modified FOLFIRINOX Regimen, NanoKnife System
- Where
- 6 sites in United States
- Volunteers
- 528 people
- Sponsor
- Angiodynamics, Inc.
Metastatic Pancreatic Adenocarcinoma
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
Patients with pancreatic cancer which has stopped responding to one or more chemotherapy drugs are asked to take part in this study.
- Trial name
- NCT02847000
- Testing
- Tetrahydrouridine, Decitabine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Yogen Saunthararajah
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Advanced Solid Tumors
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known…
- Trial name
- NCT07360314
- Testing
- M7437
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 138 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor, Advanced Solid Tumor
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05737706
- Testing
- MRTX1133
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mirati Therapeutics Inc.
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Feasibility and efficacy of combined modality intervention using chemotherapeutic agent gemcitabine with anti-angiogenic peptide vaccination targeting VRGFR1 should be determined in case of advanced/inoperable or…
- Trial name
- NCT00683358
- Testing
- VEGFR1-A24-1084 (SYGVLLWEI)
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Advanced Pancreatic Cancer
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy
- Trial name
- NCT04796948
- Testing
- Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)
10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy).
- Trial name
- NCT02702986
- Testing
- immunostimulating Interstitial Laser Thermotherapy, Laser
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Universita di Verona
Pancreas Cancer
Tumor Registry Pancreatic Cancer
The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with…
- Trial name
- AMETHYST (NCT02089269)
- Where
- Germany
- Volunteers
- 2,325 people
- Sponsor
- iOMEDICO AG
Unresectable Locally Advanced Pancreatic Cancer
A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.
Pancreatic cancer is a common malignant tumor of digestive tract, and its morbidity and mortality are increasing worldwide. Few clinical data have been published on immunotherapy for pancreatic cancer.
- Trial name
- NCT05346146
- Testing
- Sintilimab; Gemcitabine; Albumin-paclitaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Advanced Cancer, Pancreatic Cancer
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Determine Phase 2 dose of study drug
- Conditions
- Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer
- Trial name
- NivoPlus (NCT02423954)
- Testing
- Temsirolimus, Irinotecan, Irinotecan + capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Western Regional Medical Center
Pancreatic Cancer
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The secondary purpose is to assess the efficacy and…
- Trial name
- NCT03301805
- Testing
- BLEX 404
- Volunteers
- 40 people
- Sponsor
- Rgene Corporation
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC)
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- FIT-001 (NCT06026410)
- Testing
- Darlifarnib, Cabozantinib, Adagrasib
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Kura Oncology, Inc.
Liver Cancer, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Liver Cancer, Pancreatic Cancer, Brain Tumor, Breast Cancer
- Trial name
- NCT02541370
- Testing
- anti-CD133-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with…
- Conditions
- Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma
- Trial name
- NCT05651022
- Testing
- Decoy20, Tislelizumab
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Indaptus Therapeutics, Inc
Pharmacokinetics, Pancreatic Cancer
Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer
Based on the tolerability, safety and pharmacokinetics phase I/II clinical trials of ulimostat hydrochloride capsules (LH011) combined with gemcitabine hydrochloride (GEM) in locally advanced/metastatic pancreatic cancer…
- Conditions
- Pharmacokinetics, Pancreatic Cancer, Gene Polymorphisms
- Trial name
- NCT05329597
- Testing
- Genotyping
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Pancreatic Neoplasms
Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer
This trial is an efficacy and safety evaluation of the use of Utidelone injection in combination with gemcitabine for inoperable and locally inappropriate use first-line chemotherapy in the treatment of advanced pancreatic…
- Trial name
- NCT05795920
- Testing
- Utidelone injection in combination with gemcitabine
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Gastrointestinal Neoplasms, Ovarian Neoplasms
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate…
- Trial name
- GCC0319 (NCT00390182)
- Testing
- Gemcitabine
- Where
- 2 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- University of Maryland, Baltimore